Genomic Drivers of Cancer Progression and Their Implications for Targeted Therapy: A Comprehensive Review

The Genomic Basis of Cancer: A Historical Perspective

The understanding that cancer arises from heritable changes within the somatic genome, rather than from an external toxin or infectious agent alone, has developed over more than a century, but it was Peter Nowell's 1976 formulation of clonal evolution  the proposal that tumors arise from a single altered cell and progress through sequential rounds of mutation and selection  that first framed cancer progression explicitly as a Darwinian genetic process operating within the body. [1] This framework was substantially formalized in 1990 by Fearon and Vogelstein's genetic model of colorectal tumorigenesis, which proposed that cancer results from the sequential accumulation of specific driver mutations  in that model, APC, KRAS, and TP53  each conferring a discrete selective growth advantage, a model that established the template later extended across virtually every solid tumor lineage. [2]

The sequencing of the human genome, completed in the early 2000s, and the subsequent rapid fall in the cost of massively parallel (next-generation) sequencing technology transformed cancer genomics from a gene-by-gene candidate approach into a genome-wide, unbiased discovery science. Stratton, Campbell, and Futreal's 2009 review formally articulated the concept of ‘the cancer genome’ as a tractable, sequenceable entity whose complete cataloguing could in principle identify every somatic driver event in a given tumor. [3] This period also saw Hanahan and Weinberg's influential 2011 update to their ‘Hallmarks of Cancer’ framework, which organized the diverse phenotypic capabilities acquired during tumorigenesis sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, angiogenesis, invasion and metastasis, and, in the updated framework, genome instability and evasion of immune destruction as enabling characteristics  into a coherent conceptual scaffold onto which subsequent genomic discoveries could be mapped. [4]

The Sequencing Era and the Emergence of Precision Oncology

Two coordinated international efforts  The Cancer Genome Atlas (TCGA) in the United States and the International Cancer Genome Consortium (ICGC) globally  systematically sequenced tens of thousands of tumors across more than thirty cancer types over the following decade, generating what remains the most comprehensive catalog of somatic cancer genomic alterations assembled to date. [7,8] The culminating pan-cancer analysis of this effort, published by Bailey and colleagues in 2018, integrated 26 computational driver-discovery algorithms across 9,423 tumor exomes spanning all 33 TCGA projects and identified 299 statistically and biologically supported cancer driver genes, while estimating that 57% of the tumors analyzed harbored at least one potentially clinically actionable genomic event. [10] This finding  that a majority of tumors carry a genomic alteration with an existing or plausible matched therapy  is the empirical foundation of the precision oncology paradigm that organizes this review: the proposition that cancer treatment selection should be guided primarily by the specific molecular alterations present within an individual tumor rather than by its anatomical site or histological appearance alone.

Vogelstein and colleagues' companion 2013 synthesis, ‘Cancer Genome Landscapes,’ distilled this genomic complexity into an influential simplifying principle: that despite the tens of thousands of possible somatic mutations observed across the cancer genome, the number of core cellular signaling pathways that, when dysregulated, drive tumorigenesis is comparatively small  on the order of a dozen  and that most individual tumors carry driver mutations in a handful of these pathways (typically two to eight) rather than being uniquely idiosyncratic at the pathway level. [5] This pathway-centric organizing principle, further elaborated by Garraway and Lander, [6] underlies the structure of Section 4 of this review, which organizes genomic drivers by disrupted pathway rather than alphabetically by gene or by cancer type of origin.

Global and Regional Burden of Cancer

Cancer represents an immense and growing global health burden. The most recent GLOBOCAN estimates from the International Agency for Research on Cancer reported approximately 19.3 million new cancer cases and nearly 10 million cancer deaths worldwide in 2020, with incidence projected to rise substantially over subsequent decades, disproportionately in low- and middle-income countries where access to both diagnostic genomic testing and targeted therapy remains constrained. [28] In the United States, the American Cancer Society's most recent annual statistics report continues to document a decades-long decline in age-adjusted cancer mortality, a decline attributed in substantial part to the treatment advances  including genomically targeted therapy  reviewed in this paper, alongside improvements in tobacco control, screening, and early detection. [29] India's National Cancer Registry Programme has documented a rising burden domestically, with an estimated 1.39 million new cancer cases in 2020 and wide regional variation in cancer-type distribution, diagnostic infrastructure, and access to molecular testing and targeted agents  considerations discussed further in  of this review. [30,62]

Objectives of This Review

This review has four specific aims: (i) to summarize the fundamental molecular concepts  oncogene activation, tumor suppressor inactivation, genomic instability, and clonal evolution  that underlie the genomic driver paradigm  to organize and review the major classes of recurrent genomic drivers of cancer progression by disrupted oncogenic signaling pathway, drawing on pan-cancer sequencing data  to synthesize the pivotal clinical trial evidence for targeted therapies developed against each major driver class, with verified efficacy data drawn directly from primary trial publications ; and (iv) to review the mechanisms by which resistance to targeted therapy emerges and the emerging technologies and unresolved challenges that will shape the next phase of precision oncology

Fundamental Concepts in Cancer Genomics

Oncogenes and Tumor Suppressor Genes

Cancer driver genes fall into two broad functional categories, distinguished by the direction of the selective alteration required for oncogenic effect. Oncogenes are genes whose activation  through point mutation, amplification, chromosomal translocation, or overexpression  confers a gain of function that promotes proliferation or survival; a single activating allele is generally sufficient for oncogenic effect, and their normal cellular counterparts (proto-oncogenes) typically encode growth factor receptors, intracellular signal transducers, or transcription factors within proliferative signaling pathways (KRAS, EGFR, MYC, and BRAF are prototypical.. Tumor suppressor genes, conversely, normally restrain proliferation, promote apoptosis in response to DNA damage, or maintain genomic integrity, and require loss of function  classically through biallelic inactivation, consistent with Knudson's two-hit hypothesis — for their oncogenic contribution; TP53, RB1, PTEN, and BRCA1/2 are prototypical examples. This oncogene/tumor-suppressor distinction has direct therapeutic implications: activated oncogenes are frequently druggable with small-molecule inhibitors or antibodies that directly block the aberrant protein , whereas tumor suppressor loss is inherently more difficult to pharmacologically reverse and is more often exploited indirectly, for example through synthetic lethality approaches such as PARP inhibition in BRCA1/2-deficient tumors .

 Driver Mutations Versus Passenger Mutations

A typical solid tumor carries anywhere from several hundred to several thousand somatic mutations by the time of clinical diagnosis, yet only a small minority of these  typically two to eight per tumor  are believed to functionally contribute to the malignant phenotype; these are termed driver mutations, while the remainder, termed passenger mutations, are believed to be biologically inconsequential byproducts of the same mutational processes  that generated the driver events, carried along within the expanding clone without themselves conferring selective advantage. Distinguishing drivers from passengers computationally  typically through statistical tests for mutational recurrence significantly exceeding the tumor's background mutation rate, combined with structural and evolutionary conservation analyses  was the central methodological challenge addressed by the large driver-discovery consortium efforts  and remains an active area of bioinformatic and functional-genomic research. [9,10]

Mechanisms of Genomic Instability

Genomic instability  an elevated rate of acquisition of genetic alterations relative to normal somatic cells  is itself considered an enabling hallmark of cancer, because it accelerates the stochastic generation of the driver mutations on which clonal selection acts. [4,13] Several distinct mechanistic categories of genomic instability are recognized. Chromosomal instability (CIN), the most common form in solid tumors, manifests as an elevated rate of whole-chromosome or large-segment gains and losses (aneuploidy) and typically arises from defects in mitotic checkpoint fidelity, centrosome number control, or sister chromatid cohesion. Microsatellite instability (MSI) arises from loss of DNA mismatch repair (MMR) function — through germline mutation (as in Lynch syndrome) or, more commonly, somatic promoter hypermethylation of the MMR gene MLH1 — and produces a distinctive hypermutated genomic phenotype with a markedly elevated burden of small insertion-deletion mutations at short tandem-repeat sequences; MSI-high tumors carry particular relevance for immune checkpoint inhibitor therapy, . [25] Homologous recombination deficiency (HRD), arising principally from BRCA1/2 loss but also from alterations in other homologous-recombination pathway genes, impairs high-fidelity double-strand break repair and is the mechanistic basis for PARP inhibitor synthetic lethality, discussed in Section 5.6. [23,24] Finally, a growing body of mutational signature analysis  the systematic characterization of the specific base-substitution and structural-variant patterns left by distinct mutagenic processes (ultraviolet light, tobacco carcinogens, APOBEC cytidine deaminase activity, defective DNA repair)  has provided a genomic fingerprint approach to inferring the etiological processes that generated a given tumor's mutational burden, complementing the purely driver-centric analysis that is this review's primary focus. [11]

Clonal Evolution and Intratumor Heterogeneity

Building on Nowell's original clonal-evolution model, [1] contemporary deep and multi-region sequencing studies have demonstrated that tumors are rarely genetically homogeneous masses but instead comprise multiple genetically distinct subclones, related by a branching evolutionary phylogeny, that arise, expand, compete, and are selected across the course of tumor growth, treatment, and metastatic spread. [11,12] Driver mutations acquired early, prior to the most recent common ancestor of all tumor cells (‘truncal’ or ‘clonal’ mutations, such as APC loss in the Fearon-Vogelstein colorectal model) are present in every tumor cell and represent, in principle, the most reliable and durable therapeutic targets, whereas mutations acquired later (‘subclonal’ or ‘branch’ mutations) may be present in only a fraction of tumor cells and are of central importance to understanding the incomplete and heterogeneous responses, and the near-universal eventual emergence of resistance, that characterize targeted therapy in the clinic  a theme developed at length in Section 6 of this review.

Epigenetic Dysregulation as a Complementary Driver Mechanism

Alongside DNA sequence-level (genetic) alterations, heritable but reversible changes in gene expression that do not alter the underlying DNA sequence  DNA methylation, histone modification, and chromatin remodeling, collectively termed epigenetic alterations constitute a complementary and mechanistically intertwined layer of cancer driver biology. [14,15] Recurrent somatic mutations in genes directly encoding epigenetic regulators  including the chromatin-remodeling complex gene ARID1A, the histone methyltransferase EZH2, and the metabolic enzymes IDH1 and IDH2 (whose mutant products generate the oncometabolite 2-hydroxyglutarate, which globally disrupts histone and DNA demethylation) — are now recognized as bona fide cancer drivers in their own right across multiple tumor types, and are reviewed alongside the other major driver categories  Epigenetic silencing of tumor suppressor genes (for example, MLH1 promoter hypermethylation, discussed above) and epigenetically mediated non-genetic resistance to targeted therapy  further illustrate the mechanistic interdependence between the genetic and epigenetic layers of cancer driver biology that this review, while organized principally around genomic (DNA sequence-level) drivers, treats as inseparable.

Methods

Review Approach and Scope

This paper is a structured narrative review rather than a systematic review in the PRISMA sense, reflecting the nature of the underlying question: cancer genomics is a foundational mechanistic and descriptive science rather than a body of comparative randomized evidence amenable to meta-analytic pooling in the manner of a clinical intervention question. Accordingly,  mechanistic and descriptive genomic content draw on landmark discovery publications, large-scale sequencing consortium outputs, and major review syntheses, selected for their foundational or field-defining status, while Section (clinical evidence for targeted therapy) applies a more systematic standard: every efficacy figure reported is drawn directly from, and independently verified against, the primary pivotal randomized trial publication that supported regulatory approval of the corresponding agent, following the same verification discipline used in the author's related methodology for clinical outcomes synthesis.

Literature Identification

Foundational and mechanistic literature was identified through PubMed/MEDLINE searches combining terms for “cancer genomics,” “driver mutation,” “oncogene,” “tumor suppressor,” and the specific gene and pathway names , cross-referenced against the bibliographies of major reference syntheses including Hanahan and Weinberg's Hallmarks of Cancer, [4] Vogelstein et al.'s Cancer Genome Landscapes, [5] and Bailey et al.'s pan-cancer driver gene atlas. [10] Clinical trial literature  was identified by searching PubMed/MEDLINE and ClinicalTrials.gov for the pivotal phase III registration trial associated with each targeted agent discussed, cross-checked against U.S. FDA and European Medicines Agency approval documentation where available.

Data Extraction and Verification

For each targeted therapy , the following were extracted directly from the primary trial publication: trial name/acronym, agent(s) and comparator, genomic eligibility biomarker, primary efficacy endpoint, and the corresponding hazard ratio or response-rate estimate with 95% confidence interval. No efficacy statistic presented in this review was calculated, pooled, or estimated by the author; every quantitative figure is a direct, verified citation to a specific number reported in a named primary publication, consistent with this review's core commitment to reporting only authentic, source-traceable data.

 The Genomic Driver Landscape, Organized by Oncogenic Pathway

Consistent with the pathway-centric organizing principle described, [5,6] this section reviews the major recurrently altered genes and pathways that drive cancer progression, grouped into eight categories summarized in Table 1 and, for representative cancer types, quantified in Figure 2.

 

 

Figure 2. Approximate frequency of recurrently altered driver genes across selected cancer types

 

 

 

Figure 3. Core oncogenic signaling pathways and their principal targeted-therapy intercept points.

 

 

Figure 1. Pivotal-trial efficacy of genomically matched targeted therapies, grouped by driver alteration

Emerging Technologies and Future Directions

 Liquid Biopsy and Circulating Tumor DNA

Analysis of circulating tumor DNA (ctDNA) shed into peripheral blood by dying tumor cells has emerged as a minimally invasive complement, and in some contexts an alternative, to tissue biopsy for both initial genomic profiling and, of particular relevance to Section 6, serial monitoring for emergence of resistance mutations without requiring repeat invasive tissue sampling. [60] Plasma genotyping for the EGFR T790M resistance mutation, validated against tissue re-biopsy in the FLAURA and related osimertinib development program, exemplifies this application and is now incorporated into routine clinical practice for NSCLC treatment-sequencing decisions. [56] Liquid biopsy technology continues to face sensitivity limitations, particularly in patients with low disease burden or predominantly non-shedding disease patterns (e.g., CNS-only or bone-only metastasis), but its non-invasive, serially repeatable nature makes it an area of substantial ongoing technical development.

Single-Cell and Spatial Genomics

Bulk tumor sequencing, the technology underlying essentially all of the driver-discovery and clinical-trial-eligibility genomic testing discussed in, reports an average genomic profile across millions of admixed tumor and non-tumor cells and is consequently unable to directly resolve the intratumor heterogeneity and subclonal architecture described. Single-cell sequencing technologies, which generate genomic or transcriptomic profiles from individually isolated tumor cells, and spatial genomic technologies, which preserve the anatomical location of each profiled cell within the tissue architecture, together offer the prospect of directly visualizing clonal evolution, resistant-subclone emergence, and the tumor-immune microenvironment interactions relevant to immune checkpoint inhibitor response at a resolution unattainable with bulk sequencing. [61] These technologies remain predominantly research tools at present, owing to cost and throughput constraints, but are anticipated to progressively enter clinical translational use over the coming decade.

Functional Genomics and CRISPR Screening

Genome-wide CRISPR-Cas9 functional screening, in which every gene in the genome is systematically inactivated or activated in parallel within a model cell population to identify genes whose loss or gain confers a measurable phenotypic effect, has become a central discovery tool for identifying candidate synthetic-lethal drug targets (extending the BRCA1/2-PARP paradigm  to other genomic contexts) and for prospectively mapping resistance mechanisms before they are observed clinically, by systematically screening which gene perturbations confer resistance to a given targeted agent in model systems. This approach complements the retrospective, clinically driven resistance-mechanism discovery process described in Section 6 with a prospective, hypothesis-generating discovery pipeline.

 Artificial Intelligence in Genomic Interpretation

The scale and complexity of contemporary tumor genomic profiling increasingly incorporating whole-exome or whole-genome sequencing, transcriptomic profiling, and multi-omic integration rather than the smaller targeted gene panels used in earlier clinical practice  has outpaced the capacity for fully manual clinical interpretation, motivating growing use of machine-learning and, more recently, large-language-model-based tools to assist variant classification, driver-versus-passenger prioritization and matching of genomic findings to actionable therapy or clinical trial options via knowledge bases such as OncoKB. [31] These tools are increasingly integrated into molecular tumor board workflows as decision-support aids, though the clinical and regulatory validation frameworks for such AI-assisted genomic interpretation tools remain comparatively immature relative to the underlying sequencing technology itself.

DISCUSSION

The Precision Oncology Paradigm: Achievements and Scope

The evidence synthesized in documents genuinely transformative treatment effects: hazard ratios in the range of 0.30 to 0.70 across the pivotal trials reviewed represent, in aggregate, among the largest and most consistent effect sizes achieved anywhere in modern oncology drug development, and several of the agents discussed (imatinib in CML, trastuzumab in HER2-positive breast cancer) have converted diseases with historically poor prognosis into conditions compatible with near-normal or substantially extended life expectancy. [4,35,38] These successes have fundamentally restructured how new cancer drugs are developed and approved, shifting regulatory and clinical trial paradigms away from purely histology-defined disease categories and toward genomically defined patient populations  a shift epitomized by the tumor-agnostic approvals of larotrectinib and pembrolizumab, and formalized in structured frameworks such as ESCAT for ranking the clinical actionability of a given genomic finding. [32]

The Limits of the Driver Paradigm

The driver-gene paradigm reviewed in this paper, however, does not extend uniformly across all of cancer genomics. , several of the most frequently altered driver genes  MYC and mutant RAS isoforms other than KRAS G12C prominent among them  remain substantially more difficult to target directly than the receptor tyrosine kinases and fusion oncoproteins that dominate Section 5's clinical successes, reflecting underlying differences in protein structure and druggability rather than any deficiency in genomic discovery per se. Tumor suppressor gene loss  affecting the single most commonly altered gene in the pan-cancer genome (TP53), likewise remains largely therapeutically unaddressed by direct restoration approaches, with clinical benefit in TP53-altered tumors instead derived indirectly, for example through the DNA-damage-response vulnerabilities such loss can create. further qualify the paradigm's achievements: essentially no targeted therapy reviewed in Section 5 is curative in the metastatic setting, and the field's central ongoing challenge is not merely identifying new druggable drivers but converting the current pattern of initially dramatic but ultimately time-limited responses into durable disease control, whether through combination strategies, resistance-anticipating sequential therapy, or exploitation of the non-genetic adaptive resistance mechanisms.

Access, Cost, and Implementation Challenges, with Reference to India

Realizing the genomic driver paradigm's benefits in practice requires, as a precondition, access to tumor genomic profiling and to the resulting matched therapies  both of which remain substantially constrained outside high-income health systems. In India, where the National Cancer Registry Programme has documented a rising and regionally heterogeneous cancer burden, [30] access to comprehensive genomic profiling and to the newer targeted and immune therapies reviewed in Section 5 remains concentrated in a comparatively small number of tertiary cancer centers, with cost, insurance coverage, and diagnostic infrastructure availability each independently constraining real-world uptake outside these centers; Mallath and colleagues' analysis of India's cancer burden explicitly identifies this diagnostic and therapeutic infrastructure gap, rather than any lack of underlying scientific applicability, as a central barrier to translating the genomic advances reviewed in this paper into population-level outcome improvement within the Indian health system. [62] Generic and biosimilar availability of several of the older targeted agents  (imatinib prominent among them, now widely available as a low-cost generic in India) illustrates one pathway by which the cost barrier can substantially narrow over time following initial patent-protected launch, a trajectory that later-generation and immune-oncology agents have not yet uniformly followed.

Ethical and Regulatory Considerations

The tumor-agnostic, biomarker-first approval pathway pioneered by larotrectinib and pembrolizumab-for-MSI-H raises distinct regulatory and evidentiary questions relative to the traditional single-histology randomized trial model, since biomarker-defined populations, particularly for rare fusion events, are frequently too small within any single cancer type to support a conventional randomized comparison, necessitating single-arm, pooled, or basket/umbrella trial designs whose evidentiary strength differs qualitatively from the pivotal randomized trials that anchor most of Section 5's other efficacy claims (Table 2's larotrectinib and MSI-H entries are accordingly reported as objective response rate from pooled single-arm data rather than as a comparative hazard ratio). This evolution in trial design and regulatory evidentiary standards, alongside the broader question of equitable access discussed in , represents an active area of ongoing policy discussion within precision oncology.

Future Research Priorities

Building on the emerging technologies reviewed , priority areas for future research include: prospective, biomarker-stratified combination and sequencing trials explicitly designed to pre-empt rather than react to the resistance mechanisms characterized in; expanded application of single-cell and spatial genomic technologies to directly visualize, rather than infer, subclonal resistance evolution in real time; continued medicinal chemistry effort toward historically undruggable targets (MYC, non-G12C RAS isoforms) building on the KRAS G12C precedent; and health-systems and implementation-science research — particularly relevant to the Indian and other resource-constrained contexts discussed in  aimed at closing the gap between genomic and therapeutic scientific capability and equitable real-world clinical access.

CONCLUSION

The genomic driver paradigm reviewed in this paper has, over little more than two decades, transformed the conceptual and clinical practice of oncology: cancer is now understood, diagnosed, and increasingly treated as a disease defined primarily by its specific molecular alterations, organized within a comparatively small number of core oncogenic pathways , rather than by anatomical site of origin alone. The clinical trial evidence synthesized in documents some of the largest and most consistent treatment-effect sizes achieved anywhere in modern oncology, and has produced genuinely curative or near-curative outcomes in specific genomically defined contexts. Yet resistance, comprehensively characterized, remains the near-universal rule rather than the exception in metastatic disease, and substantial portions of the genomic driver landscape  MYC and tumor-suppressor loss prominent among them  remain therapeutically underaddressed despite two decades of genomic characterization. Continued progress will depend jointly on scientific advances  in resistance-anticipating combination therapy, in single-cell and functional genomic technology, and in extending the druggable genome  and on health-systems progress in equitably extending genomic testing and matched therapy access, a consideration of particular importance for large, genomically underserved health systems such as India's.

REFERENCES

1. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–28.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–767.
3. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719–724.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
5. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558.
6. Garraway LA, Lander ES. Lessons from the cancer genome. Cell. 2013;153(1):17–37.
7. International Cancer Genome Consortium (Hudson TJ, Anderson W, Artez A, et al.). International network of cancer genome projects. Nature. 2010;464(7291):993–998.
8. Weinstein JN, Collisson EA, Mills GB, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113–1120.
9. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218.
10. Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173(2):371–385.e18.
11. Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349(6255):1483–1489.
12. Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13(11):795–806.
13. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability — an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11(3):220–228.
14. Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357(6348):eaal2380.
15. Baylin SB, Jones PA. A decade of exploring the cancer epigenome — biological and translational implications. Nat Rev Cancer. 2011;11(10):726–734.
16. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139.
18. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
19. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
20. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
21. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615.
22. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–525.
23. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152–1158.
24. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921.
25. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
26. Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
27. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.
28. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
29. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49.
30. Mathur P, Sathishkumar K, Chaturvedi M, et al. Cancer statistics, 2020: report from national cancer registry programme, India. JCO Glob Oncol. 2020;6:1063–1075.
31. Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;2017:PO.17.00011.
32. Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895–1902.
33. Meric-Bernstam F, Brusco L, Shaw K, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol. 2015;33(25):2753–2762.
34. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037.
35. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (IRIS). N Engl J Med. 2003;348(11):994–1004.
36. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
37. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (HERA). N Engl J Med. 2005;353(16):1659–1672.
38. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma (IPASS). N Engl J Med. 2009;361(10):947–957.
39. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA). N Engl J Med. 2018;378(2):113–125.
40. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC (FLAURA). N Engl J Med. 2020;382(1):41–50.
41. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer (PROFILE 1014). N Engl J Med. 2014;371(23):2167–2177.
42. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer (ALEX). N Engl J Med. 2017;377(9):829–838.
43. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation (BRIM-3). N Engl J Med. 2011;364(26):2507–2516.
44. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma (COMBI-d). N Engl J Med. 2014;371(20):1877–1888.
45. Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma (coBRIM). N Engl J Med. 2014;371(20):1867–1876.
46. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation (OlympiAD). N Engl J Med. 2017;377(6):523–533.
47. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer (SOLO1). N Engl J Med. 2018;379(26):2495–2505.
48. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer (PALOMA-2). N Engl J Med. 2016;375(20):1925–1936.
49. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation (CodeBreaK 100). N Engl J Med. 2021;384(25):2371–2381.
50. de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation (CodeBreaK 200). Lancet. 2023;401(10378):733–746.
51. Hyman DM, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739.
52. Drilon A, Laetsch TW, Kummar S, et al. Larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739.
53. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer (KEYNOTE-024). N Engl J Med. 2016;375(19):1823–1833.
54. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer. J Clin Oncol. 2020;38(1):1–10.
55. Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014;11(8):473–481.
56. Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib for advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3375–3382.
57. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
58. Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384(25):2382–2393.
59. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–238.
60. Tirosh I, Suva ML. Deciphering human tumor biology by single-cell expression profiling. Annu Rev Cancer Biol. 2019;3:151–166.
61. Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20(3):e175–e186.
62. Mallath MK, Taylor DG, Badwe RA, et al. The growing burden of cancer in India: epidemiology and social context. Lancet Oncol. 2014;15(6):e205–e212.